Accelerate Diagnostics traded at $0.99 this Friday July 1st, decreasing $0.003 or 0.27 percent since the previous trading session. Looking back, over the last four weeks, Accelerate Diagnostics lost 64.95 percent. Over the last 12 months, its price fell by 87.55 percent. Looking ahead, we forecast Accelerate Diagnostics to be priced at 1.32 by the end of this quarter and at 1.22 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.04
Daily Change
4.76%
Yearly
-86.92%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abbott 110.07 1.42 1.31% -6.75%
Accelerate Diagnostics 1.04 0.05 4.76% -86.92%
Becton, Dickinson and Co. 251.29 4.76 1.93% 1.14%
Bio-Rad Laboratories 501.43 6.43 1.30% -24.79%
Bruker 62.76 0 0% -19.08%
Danaher 257.82 4.30 1.70% -5.92%
Exact Sciences 40.57 1.18 3.00% -66.97%
Hologic 69.90 0.60 0.87% 3.23%
Illumina 190.39 6.03 3.27% -59.90%
Myriad Genetics 18.56 0.39 2.15% -40.70%
NanoString Technologies 13.13 0.43 3.39% -79.04%
Pacific Biosciences Of California 4.44 0.02 0.34% -86.75%
PerkinElmer 143.77 1.55 1.09% -7.59%
Quidel 97.55 0.37 0.38% -22.14%
Thermo Fisher Scientific 547.77 4.49 0.83% 6.71%
Meridian Bioscience 30.86 0.44 1.45% 40.59%

Indexes Price Day Year
USND 11123 93.89 0.85% -24.02%
US2000 1727 18.71 1.10% -25.11%

Accelerate Diagnostics
Accelerate Diagnostics, Inc. is an vitro diagnostics company engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.